Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2023-11-02 Report Publication Anno…
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
GENFIT présente ses avancées scientifiques et stratégiques au congrès international The Liver Meeting® 2023
Report Publication Announcement Classification · 99% confidence The document is a press release dated November 2, 2023, announcing GENFIT's scientific and strategic updates to be presented at the 'The Liver Meeting® 2023' (AASLD conference). It details specific events (ACLF Day, Investigator Event, Patient Advocacy Council Meeting) and presentations regarding clinical trial results (ELATIVE® study for PBC) and diagnostic technologies (NIS2+, NIS4® for NASH/MASH). This type of announcement, which details upcoming presentations of scientific data and strategic plans, is characteristic of an Investor Presentation (IP) or a general corporate update related to investor relations activities, often preceding or coinciding with major industry conferences. Since it is a formal announcement detailing future presentations and data releases rather than the full financial report (10-K/IR) or a transcript (CT), 'Investor Presentation' (IP) is the most fitting category, as it serves to inform investors about key developments and upcoming data disclosures.
2023-11-02 French
GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023
Regulatory Filings Classification · 99% confidence The document is a press release dated November 2, 2023, announcing that GENFIT will present updates on its scientific and corporate progress at The Liver Meeting® 2023 organized by AASLD. It details specific presentations, investor events, and data disclosures related to their drug pipeline (elafibranor in PBC) and diagnostics technology. This format—a formal announcement detailing future corporate/scientific events, data presentations, and partner activities—is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT), and it is specifically focused on presenting information to investors and analysts regarding ongoing development and upcoming conference appearances, 'Investor Presentation' (IP) is the most fitting category, although it is structured as a press release announcing participation in a conference. Given the content heavily focuses on scientific updates, data presentation schedules, and investor events, IP is preferred over the generic RNS.
2023-11-02 English
GENFIT annonce une publication dans Nature Medicine confirmant la performance de sa technologie de diagnostic dans la NASH
Regulatory Filings Classification · 100% confidence The document is a press release from GENFIT dated September 26, 2023, announcing the publication of data in the scientific journal *Nature Medicine* regarding the performance of its NIS4® diagnostic technology for NASH. This type of announcement, detailing scientific progress, clinical trial results, or regulatory milestones, is typically classified as an Investor Presentation (IP) if it were a deck, or often falls under general Investor Relations communication. Since it is a formal announcement of significant scientific/clinical validation that impacts investor understanding of the company's assets (diagnostic technology), and it is not a mandatory periodic financial report (like 10-K or IR), nor a simple earnings release (ER), the most fitting category among the provided options that covers detailed scientific/strategic updates aimed at investors is Investor Presentation (IP). It is not a Call Transcript (CT), a formal Audit Report (AR), or a simple Report Publication Announcement (RPA) because it contains substantial content about the results, not just a notice that a report is available. Given the detailed nature of the scientific findings and their implications for regulatory approval (FDA), IP is the best fit.
2023-09-26 French
GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology
Regulatory Filings Classification · 100% confidence The document is a press release dated September 26, 2023, announcing that GENFIT's NASH diagnostic technology data has been published in the scientific journal *Nature Medicine*. The text focuses on the results of a study conducted by the FNIH's NIMBLE project, confirming the performance of the NIS4® technology. This is an announcement of scientific/research findings and their publication, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is an announcement about a scientific/research milestone and publication, it fits best under the general category for regulatory announcements or significant corporate news that doesn't fit other specific codes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general press release announcing a significant corporate/scientific event, although 'Report Publication Announcement' (RPA) is also plausible if the primary intent was just to announce the publication. However, the content is substantive news about research validation, making RNS (general regulatory/corporate announcement) a strong fit, or potentially IP if it were an investor presentation, but it is a press release. Given the nature of announcing scientific validation and publication, RNS serves as the best general category for non-standard, material corporate news announcements.
2023-09-26 English
GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update
Earnings Release Classification · 95% confidence The document is a press release titled 'GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update'. It contains key financial highlights, business updates, and forward-looking statements. While it references a 'Half Year Business and Financial Report' being available elsewhere, the document itself serves as the initial announcement of these results, which fits the definition of an Earnings Release (ER). H2 2023
2023-09-20 English
GENFIT : Résultats financiers du premier semestre 2023 et point sur les activités de la Société
Earnings Release Classification · 99% confidence The document is titled "GENFIT : Résultats financiers du premier semestre 2023 et point sur les activités de la Société" (GENFIT: First Half 2023 Financial Results and Company Activity Update). It explicitly details financial results for the first half of 2023, discusses clinical trial progress (Phase 3 ELATIVE® results), pipeline updates, and governance changes. The footnote explicitly states: "Le Rapport Semestriel d'Activité et Financier a été mis à la disposition du public..." (The Semi-Annual Activity and Financial Report has been made available to the public...). This content structure—a comprehensive review of a six-month period's financial and operational performance—is characteristic of an Interim/Quarterly Report, which corresponds to the 'IR' code. It is too detailed to be just an Earnings Release (ER) and is not the full Annual Report (10-K). H1 2023
2023-09-20 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.